NervGen's RESTORE trial, which dosed its first patient Oct. 12, is a rare pivotal spinal cord injury study built on the ...
The FDA approved the anti-IL6R drug for thyroid eye disease, but drugs targeting IGF-1R are still regarded as the gold ...
Bipartisan House legislation would exempt ostomy and urological supplies from Medicare competitive bidding for five years, as ...
Industry groups largely support the FDA’s proposal to let distributed manufacturing networks register as one establishment, ...
The Expert Panel for Cosmetic Ingredient Safety accepted the recommendations for prostaglandin analogues from the Read-Across ...
City Therapeutics and Iambic Therapeutics raised $200m and $150m, respectively, in their initial public offerings, bringing ...
Fresenius Kabi has announced a leadership change that will see Marc-Alexander Mahl take over responsibility of the business ...
The European Medicines Agency’s human medicines committee has endorsed Eli Lilly’s once-daily pill for obesity and type 2 ...
Ascendis Pharma’s once-weekly achondroplasia treatment, Yuviwel, which is already approved in the US, is a step closer to ...
A rundown of the ten biggest mid-cap risers and decliners of the year to date, with catalysts which could shape big pharma’s ...
Abbott's TECTONIC data at TCT, BiVACOR's artificial heart expansion, Medtronic's Sphere-9 VT push and Corvia's RESPONDER-HF ...
The US FDA has issued an early alert for some Commander M delivery systems used with Edwards Lifesciences’ Sapien M3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results